Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are associated with albuminuria in hypertensive African Americans: The HyperGEN study

American Journal of Nephrology

Volumn 29, Issue 6, 2009, Pages 626-632

  Freedman, Barry I ^a   Kopp, Jeffrey B ^b   Winkler, Cheryl A ^c   Nelson, George W ^c   Rao, D C ^d   Eckfeldt, John H ^e   Leppert, Mark F ^f   Hicks, Pamela J ^a   Divers, Jasmin ^a   Langefeld, Carl D ^a   Hunt, Steven C ^f  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c SAIC FREDERICK INC   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

African Americans; Albuminuria; Chronic kidney disease; Essential hypertension; HyperGEN study; MYH9 gene

Indexed keywords

MYOSIN HEAVY CHAIN; MYOSIN HEAVY CHAIN 9; UNCLASSIFIED DRUG;

ADULT; AFRICAN AMERICAN; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ETHNIC DIFFERENCE; GLOMERULUS FILTRATION RATE; HAPLOTYPE; HUMAN; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MICROALBUMINURIA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

AFRICAN AMERICANS; ALBUMINURIA; CROSS-SECTIONAL STUDIES; HAPLOTYPES; HUMANS; HYPERTENSION; MOLECULAR MOTOR PROTEINS; MYOSIN HEAVY CHAINS; POLYMORPHISM, SINGLE NUCLEOTIDE; UNITED STATES;

EID: 58249096429     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000194791     Document Type: Article

References (28)

1. Freedman BI, Iskandar SS, Appel RG: The link between hypertension and nephrosclerosis. Am J Kidney Dis 1995;25:207-221.
2. United States Renal Data Systems Annual (USRDS) 2006 Report. Am J Kidney Dis 2007;49:S1.
3. Schlessinger SD, Tankersley MR, Curtis JJ: Clinical documentation of end-stage renal disease due to hypertension. Am J Kidney Dis 1994;23: 655 - 6 60.
4. Zarif L, Covic A, Iyengar S, Sehgal AR, Sedor JR, Schelling JR: Inaccuracy of clinical phenotyping parameters for hypertensive nephrosclerosis. Nephrol Dial Transplant 2000;15:1801-1807.
5. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J: Blood pressure and end-stage renal disease in men. N Engl J Med 1996;334: 13-18.
6. Perneger TV, Whelton PK, Klag MJ: Race and end-stage renal disease. Socioeconomic status and access to health care as mediating factors. Arch Intern Med 1995;155:1201-1208.
7. Song EY, McClellan WM, McClellan A, Gadi R, Krisher J, Clay M, Freedman BI: The effect of neighborhood characteristics on family history (FH) of ESRD (abstract). J Am Soc Nephrol 2008, in press.
8. Freedman BI, Volkova N V, Satko SG, Krisher J, Jurkovitz C, Soucie JM, McClellan WM: Population-based screening for family history of end-stage renal disease among incident dialysis patients. Am J Nephrol 2005;25: 529-535.
9. Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, Coresh J, Patterson N, Tandon A, Powe NR, Fink NE, Sadler JH, Weir MR, Abboud HE, Adler SG, Divers J, Iyengar SK, Freedman BI, Kimmel PL, Knowler WC, Kohn OF, Kramp K, Leehey DJ, Nicholas SB, Pahl MV, Schelling JR, Se-dor JR, Thornley-Brown D, Winkler CA, Smith MW, Parekh RS: MYH9 is associated with nondiabetic end-stage renal disease in African A mericans. Nat Genet 2008;40: 1185-1192 .
10. Kopp JB, Smith MW, Nelwson GW, Johnson RC, Freedman BI, Bowden DW, Oleksyk T, McKenzie LM, Kajiyama H, Ahuja TS, Berns JS, Briggs W, Cho ME, Dart RA, Kimmel PL, Korbet SM, Michel DM;Mokrzycki MH, Schelling JR, Simon E, Trachtman H, Vlahov D, Winkler CA: MYH9 is a major-effect risk gene for focal segmental glomeulosclerosis. Nat Genet 2008;40:1175-1184.
11. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER III, Norris K, O'Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT Jr, Xu S: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001;285:2719-2728.
12. Appel LJ, Wright JT Jr, Greene T, Kusek JW, Lewis JB, Wang X, Lipkowitz MS, Norris KC, Bakris GL, Rahman M, Contreras G, Rostand SG, Kopple JD, Gabbai FB, Schulman GI, Gassman JJ, Charleston J, Agodoa LY: Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med 2008;168:832-839.
13. Rostand SG, Brown G, Kirk KA, Rutsky EA, Dustan HP: Renal insufficiency in treated essential hypertension. N Engl J Med 1989;320:684-688.
14. Freedman BI, Spray BJ, Tuttle AB, Buckalew VM: The familial risk of end-stage renal disease i n A f r ican Americans. A m J Kid ney Dis 1993;21:387-393.
15. Williams RR, Rao DC, Ellison RC, Arnett DK, Heiss G, Oberman A, Eckfeldt JH, Leppert MF, Province MA, Mockrin SC, Hunt SC: NHLBI family blood pressure program: methodology and recruitment in the Hyper-GEN network. Hypertension genetic epidemiology network. Ann Epidemiol 2000;10: 389-400.
16. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470.
17. Stephens M, Smith NJ, Donnelly P: A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68: 978-989.
18. Faul C, Asanuma K, Yanagida-Asanuma E, Kim K, Mundel P: Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol 2007;17:428-437.
19. Kaplan JM, Kim SH, North KN, Rennke H, Correia LA, Tong HQ, Mathis BJ, Rodriguez-Perez JC, Allen PG, Beggs AH, Pollak MR: Mutations in ACTN4, encoding alpha-ac-tinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 2000;24:251-256.
20. Lenkkeri U, Mannikko M, McCready P, Lamerdin J, Gribouval O, Niaudet PM, Antignac CK, Kashtan CE, Homberg C, Olsen A, Kestila M, Tryggvason K: Structure of the gene for congenital nephrotic syndrome of the Finnish type (NPHS1) and characterization of mutations. Am J Hum Genet 1999;64: 51-61.
21. Mukerji N, Damodaran TV, Winn MP: TRPC6 and FSGS: the latest TRP channelopathy. Biochim Biophys Acta 2007;1772: 859-868.
22. Fogo A, Breyer JA, Smith MC, Cleveland WH, Agodoa L, Kirk KA, Glassock R: Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators. Kidney Int 1997;51: 244-252.
23. Freedman BI, Iskander SS, Buckalew VM Jr, Burkart JM, Appel RG: Renal biopsy findings in presumed hypertensive nephrosclerosis. Am J Nephrol 1994;1 4: 90 -94.
24. Marcantoni C, Ma LJ, Federspiel C, Fogo AB: Hypertensive nephrosclerosis in African Americans versus Caucasians. Kidney Int 2002;62:172-180.
25. Freedman BI, Hicks PJ, Bostrom MA, Cunningham ME, Liu M, Divers J, Kopp JB, Winkler CA, Nelson GW, Langefeld CD, Bowden DW: Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. Kidney International 2009, in press. DOI: 10.1038/ ki.2008.701.
26. Freedman BI, Sedor JR: Hypertension-associated kidney disease: Perhaps no more. J Am Soc Nephrol 2008;19:2047-2051.
27. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, Schneider KA: Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 1989;13: 180-193.
28. Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD: Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. JA MA 1992;268: 3085-3091.